|[March 08, 2013]
Research and Markets: PharmaPoint Drug Evaluation Report - Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/48jdq7/brivaracetam)
has announced the addition of GlobalData's new report "Brivaracetam
(Epilepsy) - Forecast and Market Analysis to 2022" to their offering.
PharmaPoint Drug Evaluation report, Brivaracetam (Epilepsy) - Forecast
and Market Analysis to 2022. Epilepsy is a brain disorder characterized
by spontaneously occurring and recurrent seizures. The market is heavily
driven by the sales of antiepileptic drugs (AEDs) targeted at seizure
reduction. The AED market is currently dominated by UCB's Keppra and
GlaxoSmithKline's Lamictal. Although both drugs have experienced
significant generic erosion, they form the mainstay of epilepsy
treatment in the nine markets and will continue to have significant
market share during the forecast period.
Other key drugs include older generation AEDs such as Pfizer's Dilantin,
Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have
significant usage due to their longevity in the market. However, the AED
dominance landscape will continue to shift towards newer generation
drugs particularly following the recent market entry of
GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer
first-in-class mechanisms of action.
Brivaracetam (BRV), which is an analog of the AED levetiracetam
(Keppra), is being developed by UCB as an adjunctive therapy for the
treatment of epilepsy, partial-onset seizures, and epilepsy in pediatric
patients. It is an orally-administered small molecule that acts by
binding to the synaptic SV2A protein. However, unlike levetiracetam, BRV
also shows inhibitory activity at neuronal voltage-dependent sodium
channels, which gives it a broader spectrum of activity.
- Overview of Epilepsy, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on
the competitive landscape.
- Detailed information on Brivaracetam including product description,
safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Brivaracetam for the top six countries from 2012 to
- Sales information covered for the US, France, Germany, Italy, Spain
and the UK
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/48jdq7/brivaracetam
Source (News - Alert): GlobalData
[ Back To Technology News's Homepage ]